Last Price
21.53
Today's Change
+0.69 (3.31%)
Day's Change
21.14 - 21.94
Trading Volume
330,006
Market Cap
1 Billion
Shares Outstanding
90 Million
Avg Volume
874,400
Avg Price (50 Days)
20.72
Avg Price (200 Days)
24.45
PE Ratio
-7.76
EPS
-2.77
Earnings Announcement
04-Nov-2024
Previous Close
20.84
Open
21.52
Day's Range
21.145 - 21.94
Year Range
16.55 - 32.525
Trading Volume
330,172
1 Day Change
3.11%
5 Day Change
12.22%
1 Month Change
11.93%
3 Month Change
3.07%
6 Month Change
-20.02%
Ytd Change
-27.15%
1 Year Change
-6.48%
3 Year Change
-33.75%
5 Year Change
64.67%
10 Year Change
-10.46%
Max Change
-10.46%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.